Madison, WI (PRWEB) May 24, 2013
Quincy Bioscience, a leading research company committed to the discovery and development of calcium-binding proteins to support healthy living, is pleased to announce publication of safety assessment study of apoaequorin in Food and Chemical Toxicology, an international journal published for the British Industrial Biological Research Association.
The objective of the study was to investigate potential adverse effects, if any, of apoaequorin, in rats following subchronic administration. Based on the results of this study, the No Observed-Adverse-Effect Level (NOAEL) for apoaequorin was determined as 666.7 mg/kg bw/day, the highest dose tested. Administration of the apoaequorin preparation did not result in any mortality. There were no further clinical or opthalmological signs, body weight, body weight gain, food consumption, food efficiency, clinical pathology, or histopathological changes attributable to administration of apoaequorin.
Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health. Apoaequorin is included in the dietary supplement Prevagen. It is used to improve mild memory loss associated with aging.
About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin focused on the discovery, development and commercialization of novel technologies to support good health in aging. The company’s products focus on supporting memory and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Read the full story at http://www.prweb.com/releases/2013/5/prweb10765048.htm.
Copyright©2012 Vocus, Inc.
All rights reserved